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Abstract
Background: Osteosarcoma is a highly malignant bone neoplasm of children and young adults. It is characterized
by extremely complex karyotypes and high frequency of chromosomal amplifications. Currently, only the
histological response (degree of necrosis) to therapy represent gold standard for predicting the outcome in a
patient with non-metastatic osteosarcoma at the time of definitive surgery. Patients with lower degree of necrosis
have a higher risk of relapse and poor outcome even after chemotherapy and complete resection of the primary
tumor. Therefore, a better understanding of the underlying molecular genetic events leading to tumor initiation
and progression could result in the identification of potential diagnostic and therapeutic targets.
Methods: We used a genome-wide screening method – array based comparative genomic hybridization (array-
CGH) to identify DNA copy number changes in 48 patients with osteosarcoma. We applied fluorescence in situ
hybridization (FISH) to validate some of amplified clones in this study.
Results: Clones showing gains (79%) were more frequent than losses (66%). High-level amplifications and
homozygous deletions constitute 28.6% and 3.8% of tumor genome respectively. High-level amplifications were
present in 238 clones, of which about 37% of them showed recurrent amplification. Most frequently amplified
clones were mapped to 1p36.32 (PRDM16), 6p21.1 (CDC5L, HSPCB,  NFKBIE), 8q24, 12q14.3 (IFNG), 16p13
(MGRN1), and 17p11.2 (PMP22 MYCD, SOX1,ELAC27). We validated some of the amplified clones by FISH from
6p12-p21, 8q23-q24, and 17p11.2 amplicons. Homozygous deletions were noted for 32 clones and only 7 clones
showed in more than one case. These 7 clones were mapped to 1q25.1 (4 cases), 3p14.1 (4 cases), 13q12.2 (2
cases), 4p15.1 (2 cases), 6q12 (2 cases), 6q12 (2 cases) and 6q16.3 (2 cases).
Conclusions: This study clearly demonstrates the utility of array CGH in defining high-resolution DNA copy
number changes and refining amplifications. The resolution of array CGH technology combined with human
genome database suggested the possible target genes present in the gained or lost clones.
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Background
Osteosarcoma (OS) is a primary malignant tumor of bone
arising from primitive bone-forming mesenchymal cells
and it accounts for approximately 60% of malignant bone
tumors in the first two decades of life [1]. These tumors
typically arise in the metaphyseal regions of long bones,
with the distal femur, proximal tibia and proximal
humerus. A significant number of osteosarcomas are of
conventional type which can be subdivided into three
major categories based on their predominant differentia-
tion of tumor cells: osteoblastic, chondroblastic, and
fibroblastic. Currently, only the histological response
(degree of necrosis) to therapy represent gold standard for
predicting the outcome in a patient with non-metastatic
osteosarcoma at the time of definitive surgery [2]. Patients
with lower degree of necrosis have a higher risk of relapse
and poor outcome even after chemotherapy and complete
resection of the primary tumor. Therefore, a better under-
standing of the underlying molecular genetic events lead-
ing to tumor initiation and progression could result in the
identification of potential diagnostic and therapeutic
targets.
Chromosomal aberrations in osteosarcoma are highly
complex and characterized by high frequency of amplifi-
cations. These amplifications may result in the overexpres-
sion of genes and contribute to the genomic instability in
osteosarcoma. The identification of genes within the
amplified sites is crucial for understanding the biology
and clinical behavior of osteosarcoma. Until, recently
gene amplification has been detected by PCR, southern
blot analysis or FISH-based approach using gene specific
probes. These techniques are inherently restricted to the
previously known amplified genes in the genome. In con-
trast, genome-wide screening of amplified chromosomal
regions with CGH has become an important tool for the
detection of amplified regions in the tumor genome. So
far published chromosomal CGH studies in osteosarcoma
have identified several high-level chromosomal amplifi-
cations at 1p22, 1p31, 1q21, 1q23, 2q24, 3p25, 3q26,
6q24.3, 4q12, 5p14-p15, 5q33, 6p12-p21, 6q24.3, 7p21-
p22, 8q12-q23, 10p21, 10q11.1, 10q22, 11q13, 11q23,
12p13, 12q12-q15, 17p11.2, 17q21, 18q22, 19p13.1 and
20p11.2 [3-7]. However, conventional CGH has limited
sensitivity and resolution (~10–15 megabases) because of
its dependence on the morphology of metaphase chromo-
somes. In addition, extensive follow-up work is required
to identify candidate genes after regions of gain or loss
have been identified. Recently, novel method termed as
array-based comparative genomic hybridization (array
CGH) has been described, which enables high throughput
quantitative measurement of high-resolution DNA copy
number changes throughout the genome [8]. This
method is based on hybridization of differentially labeled
test and reference DNAs to an array of mapped human
genomic DNA fragments (~100–200 kb) and has been
recently applied to human and mouse tumors [9-14]. To
identify high-resolution copy number, we used array CGH
to the panel of 48 tumors. The resolution of array CGH
technology combined with human genome database not
only allowed a precise identification of amplicons but
also suggested the possible target genes within the
amplicons.
Methods
Patient samples
A total of 48 tumors from 42 patients (20 males and 22
females) were collected from the Texas Children's Cancer
Center, Houston, TX (tumors 193, 196, 204, 209, 221,
226, 248, 274, 295, 311, 326, 341, 345, 360, 400, 464,
481, 501, 527, 591 and 606) and Memorial Sloan Ketter-
ing Cancer Center, New York (tumors 06, 15, 24, 25, 27,
29, 32, 34, 40, 48, 68, 76, 78, 79, 80, 82, 83, 85, 88, 95,
98, 99, 102, 123, 423, 425, and 474). All tissues in this
study were obtained after IRB approved informed con-
sents were signed. The age at diagnosis ranged from 5
years to 71 years at diagnosis. The histological informa-
tion of 42 patients is presented in Table 1.
Array CGH
The array used in this study consists of 967 human BACs,
which were spaced approximately 3 megabase across the
whole genome. These arrays were obtained from Spectral
Genomics, Houston, TX. The experiments were performed
according to the manufacturer's protocol. Arrays were pre-
hybridized with human Cot-I DNA (GIBCO Invitrogen,
Carlsbad, CA) and salmon testes DNA to block the repet-
itive sequences on BACs. One microgram of normal DNA
(reference) and tumor DNA (test) was labeled with cy5-
dUTP and cy3-dUTP respectively, by random priming. To
avoid dye bias, we performed dye swap experiments for
each sample. The probe mixture is dissolved in hybridiza-
tion mixture, denatured, cooled, and mounted with 22 ×
60 mm coverslip. Hybridizations were performed in
sealed chambers for 16–20 hours at 60°C. After post
hybridization washes, arrays were rinsed, dried with com-
pressed air, and scanned into two 16-bit TIFF image files
using Gene Pix 4000A two-color fluorescent scanner
(Axon Instruments, Inc., Union City, CA) and quantitated
using GenePix software (Axon Instruments, Union City,
CA).
Data processing and analysis
After scanning of the slide, the fluorescent intensities of
the green and red channels were background subtracted.
The resulting values were normalized by intensity based
local weighted regression method (Lowess) to correct for
systematic bias in dye labeling and fluorescent intensity
[15]. Then the ratio of the red/green channel of each clone
was calculated and log base 2 transformed (log ratios).BMC Cancer 2004, 4:45 http://www.biomedcentral.com/1471-2407/4/45
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Table 1: Histological information on 48 osteosarcoma samples
Tumor 
No.
Sex Age-Dx Site Histological Subtype Type Metastatic 
Disease
Huvos 
Grade
Response
06 Female 7 Distal Femur NA Biopsy L II PR
15 Male 35 Distal Femur Osteoblastic+MFH-Like Biopsy L
24 Female 16 Clavicle Chondroblastic Biopsy L Minimal
25 Male 8 Skull Osteoblastic Mets L
27 Female 34 Ischium Mixed 
Chondroblastic+Fibroblastic-Like
Mets L
29 Male 19 Ilium NA Biopsy M II PR
32 Female 25 Ilium Chondroblastic Biopsy L Minimal
34 15 Femur Chndroblastic And 
Osteoblastic
Biopsy L II PR
40 Female 11 Left Distal Femur Giant Cell Definitive None IV GR
48 Female 32 Proximal Tibia Osteo/Fibro/Chondroblastic Definitive None I PR
68 Male 18 Femur Telangectactic Mets
76 Female 20 Thigh N/A Biopsy L
78 Male 5 Humerus N/A Biopsy L III GR
79 Male 9 Tibia Telangectactic Mets L III GR
80 Male 46 Tibia N/A Biopsy L I PR
82 Male 23 Humerus Osteoblastic Mets L I PR
83 Female 12 Femur Telangiectatic Biopsy L IV GR
85 Male 34 Femur Fibroblastic Biopsy L I PR
88 Male 17 Humerus Chndorblastic Biopsy L IV GR
95 Male 71 Femur Giant Cel Rich Biopsy L
98 Female 31 Ilium Epithelioid Biopsy L
99 Female 22 Humerus N/A Biopsy L
102 Male 70 Humerus Fibrohistiocytic Mets L
123 Female 16 Femur N/A Biopsy L I PR
209 Female 17 Distal Femur Osteoblastic Biopsy No II PR
221 Female 17 Femur Osteoblastic Biopsy No IV GR
248 Female 13 Tibia Pleiomorphic Biopsy No ?
311 Female 13 Distal Femur Osteoblastic Definitive No III GR
326 Female 20 Femur Osteoblastic Pul Met Yes IV GR
341 Male 12 Lemur Fibroblastic Biopsy N II PR
345 Male 10 Distal Femur Osteosarcoma Biopsy No IV GR
360 Female 18 Distal Femur Osteoblastic Biopsy Yes IV GR
400 Female 15 Distal Femur Chondroblastic Yes
423 Male 30 Proximal Humerus Giant Cell Definitive None I PR
425 Male 24 Tibia N/A Biopsy Proximal 
Femur
IP R
474 Female 17 Pelvis Chondroblastic Biopsy None II PR
591 Male 15 Proximal L Tibia Telangectactic Definitive No II PR
193a Female 17 Distal Femur Osteoblastic Biopsy No
196a Female 15 Distal Femur Osteoblastic Pul Met Yes
274b Male 13 Distal Femur Osteoblastic//Chondroblastic Biopsy No II PR
295b Male 13 Femur Osteoblastic//Chondroblastic Yes II PR
464c Female 15 Distal Femoral Head Osteoblastic/Spindle Cell/
Chondroblastic
Biopsy No II PR
501c Female 15 Femur Osteoblastic Definitive No II PR
606c Female 14 Distal Femur Osteoblastic Biopsy Yes II PR
481d Male 10 Distal Femur Osteoblastic Biopsy No II PR
527d Male 10 Proximal Tibia Osteoblastic Definitive Yes III GR
204e Female 18 Distal Femur Osteoblastic Biopsy No I PR
226e Female 18 Distal Femur Telangectactic Definitive No I PR
a, b, c, d, e-Tumor samples obtained from the same patient.BMC Cancer 2004, 4:45 http://www.biomedcentral.com/1471-2407/4/45
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Each experiment was repeated once with dye reversal to
addressing the confounding effect of the dye and experi-
ment. The average of the dye-reversal experiment pair was
calculated by reversing the sign of one experiment so that
the log ratio reflects the tumor versus normal ratio.
We developed a new analytical method called invariant
analysis to define the significant copy number changes.
This method is designed to: i) increase the power of the
analysis by combining all the cases in our dataset to define
an invariant population (unchanged population); and, ii)
to address the signal to noise differences among individ-
ual cases due to sample and hybridization variability. Our
goal is to define a set of unchanged clones that can be used
to calculate the upper and lower bound thresholds of the
log ratios for the unchanged population in each experi-
ment. First, we calculated the variance of each clone from
all the experiments. We computed the p-values of the each
clone by comparing to the clone with median variance
using chi-square distribution http://linus.nci.nih.gov/
~brb/TechReport.htm. The clones that have p-value
greater than preset cutoff 0.9 were considered as invariant
clone set, i.e. clones that do not vary significantly in all
experiments. Then the mean and standard deviation of
the log ratios of these invariant clones in each experiment
were calculated. The clones with log ratios that exceed
mean +/- 2 × SD of the invariant set were considered gains
and losses, respectively. For amplification and
homozygous deletions, clones were defined to have at
least 2 fold of the upper bound threshold and 4-fold of
lower bound threshold, respectively. The gene(s) present
in the clones were identified using UCSC browser http://
genome.ucsc.edu/cgi-bin/hgGateway ?org=human by
downloading gene table (refFlat) from human gene
assembly, July 2003. We search the candidate genes based
on linear mapping position, which include 100 kb up and
downstream from the clone center position. The supple-
mental data for this article is available at: https://big
file.bcm.tmc.edu/outbound/prao/supplemen-
tal%20data%20Man%20et%20al.xls
Statistical analysis
Significant clones in 6p, 8q, 12q and 17p amplicons were
calculated using 2-sample t-test with randomized variance
model http://linus.nci.nih.gov/~brb/TechReport.htm.
The experiments in each of the two groups, amplification
and normal, used for comparison were defined based on
the invariant analysis (see above). The clones that have p
<0.001 were considered as significant. We chose a strin-
gent cutoff to minimize the multiple testing problem.
FISH
FISH was performed to validate and quantify chromo-
somal amplicons using clones from 6p12-p21 (RP11-
91E11, AL391415, RP11-81F7, RP11-79I2, RP11-90H17
and RP11-79F13), 8q24.3 (RP11-89K10), and 17p11.2-
p12 (RP11-64B12, RP11-89K6 and RP11-189D22 on
tumors metaphase/interphase cells from cases 274, 364,
425, 426, 527 and 628. We confirmed the map positions
of all clones on normal human metaphase cells by FISH.
The bacterial artificial chromosome (BAC) clones, and
centromeric clone from 6 (pEDZ6) were labeled with
Spectrum Red or Spectrum Green (Vysis, Downers Grove,
IL) by nick translation. Hybridization and FISH analysis
was performed as described previously [16].
Results
To define the gains and losses in our experiments, we used
invariant analysis for the first time to describe genomic
changes by array CGH. In this method, we defined an
invariant clone set that has low variance of log ratios
among all the array experiments. After the mean and
standard deviation of the log ratios in the invariant set of
each experiment were calculated, clones that have higher
or lower log ratios than the mean +/- 2SD of the invariant
set (upper bound and lower bound) were used to define
gains and losses. We chose to use this method because it
addresses some of the shortcomings of the modeling
method, such as using all information provided in a set of
experiment to determine the unchanged population
instead of using one experiment at a time. However, the
variation of each experiment is accounted for because the
thresholds are calculated using the invariant set from each
experiment. It also does not require a separate reference
set for comparison. Finally, it provides an adjustable cut-
Frequency of DNA copy number changes identified by array  CGH in 48 osteosarcomas Figure 1
Frequency of DNA copy number changes identified by array 
CGH in 48 osteosarcomas. The gains and losses are depicted 
as green and red color bars respectively. Clones are 
arranged from chromosome 1 to 22 and within each chro-
mosome on the basis of UCSF mapping position.BMC Cancer 2004, 4:45 http://www.biomedcentral.com/1471-2407/4/45
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off to optimize the thresholds to the training data, if
provided.
The amplified and homozygously deleted clones were
defined to have at least 2 fold of the upper bound and 4-
fold of lower bound, respectively. Figure 1 summarizes
the high-resolution DNA copy number changes identified
by array CGH in 48 osteosarcomas derived from 42
patients. Copy number changes were detected involving
small genomic regions, whole chromosomes, and chro-
mosomal arms showing homozygous deletions and high-
level amplifications.
Overview of genomic profiles
Copy number changes excluding clones from sex chromo-
somes were involved in a significant fraction of most
tumor genome. The estimated average genomic distance
between clones was ~3–4 Mb. The frequency of clones
showing gains (79%) was greater than losses (66%).
High-level amplifications and homozygous deletions
constitute 28.6% and 3.8% of tumor genome respectively.
The most frequently deleted clones were identified from
the chromosomal regions 2q31.1, 3p14.1, 4p16.2, 6q12,
6q21, 6q27, 7q35, 10p15.1, 10q22-q23, 10q25-q26,
11q25, 13q12.2, 13q14.3, 13q22.1, 17p13.3 and 17q12
(Table 2). Most frequently gained clones were mapped to
chromosome 1p36, 4p16, 6p12-p21, 8q21, 8q23-q24,
12q14.3, 16p13.3, 16q24.3, 17p11-p12, 19p13.3 and
21q22.3 (Table 3). We explored the possible statistical
relationship between copy number alterations and histo-
logical and clinical parameters. We found no significant
relationship between copy number changes and primary/
metastatic disease, or histological type or histological
response. This may be due to the involvement of large
number of genomic loci and insufficient sample size.
Homozygous deletions were noted for 32 clones (3.8%).
Recurrent homozygous deletions were noted for 7 clones
that are were mapped to 1q25.1 (4 cases), 3p14.1 (4
cases), 13q12.2 (2 cases), 4p15.1 (2 cases), 6q12 (2
cases), 6q12 (2 cases) and 6q16.3 (2 cases). Figure 2A is
showing a homozygous deletion at 3p14.1 in tumor 06.
Loss of 6q12 region was noted in 35% of the osteosarco-
mas. This region was covered with four clones spanning
~4.2 Mb. Two tumors (tumor 27 and 345) showed low
intensity ratios indicting homozygous deletions in this
region, one tumor (tumor 345) showed all 4 deleted
clones spanning ~4.2 Mb with RP1-129L7 having the
lowest ratio intensity decrease. In another case (tumor
27), two clones (RP1-46B1 and RP1-129L7) showed
decreased intensity ratios indicating homozygous dele-
tions. Both these clones spanning approximately 2.6 Mb
of 6q12 region.
Table 2: Most frequently lost clones.
Clone Map Position (Mb) Cyto Position Frequency (%) Genes
RP11-79K15 31.9 17q12 27
RP1-140C12 170.4 6q27 22.9 PSMB1
RP11-90M15 24.8 13q12.2 20.8
RP11-79I4 73.4 13q22.1 20.8 KLF12
RP11-79K22 101.7 6q16.3 20.8 MTMR6, NUPL1
AC004889 148.401 7q35 20.8 OR2A4
RP11-89H7 116.5 10q25.3 18.8
AL359836 128.22 10q26.11 18.8
RP11-80L16 67 6q12 18.8
RP11-80D10 2.8 10p15.1 16.7
AC021027 84.029 10q22.3 16.7
RP11-79E24 88 10q23.2 16.7
RP11-90B19 131.5 10q26.3 16.7
RP11-835G21 143.17 11q25 16.7
RP11-80H2 50 13q14.3 16.7
RP11-81D9 72.8 13q22.1 16.7
RP5-1029F21 1.21 17p13.3 16.7
AC020681 175.95 2q31.1 16.7 PDK1
RP11-89A12 68 3p14.1 16.7
RP11-9A1 71.28 3p14.1 16.7
RP11-492I23 3.64 4p16.2 16.7
RP1-46B1 69.4 6q12 16.7 BAI3
RP3-454N4 106 6q21 16.7BMC Cancer 2004, 4:45 http://www.biomedcentral.com/1471-2407/4/45
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Amplification is a frequent phenomenon in osteosarcoma
Previous studies using CGH have identified several chro-
mosomal amplification sites in osteosarcoma. Because of
the limitation of the method, it fails to pinpoint the
precise site of amplicon. However, the present study by
array CGH has identified 238 clones (28.6%) with high-
level amplifications. Recurrent amplifications were noted
in ~37% of the total amplified clones (Figure 3). These
amplified clones were mapped to 1p22, 1p31.1 (ROR1),
1p36.1 (PRDM16), 1q21, 1q23 (TNFF6), 2q24, 3p25,
3q26.1, 4p16.3, 5p14, 5q33, 6p11.2-p21, 7p21, 8q12.1,
8q24.13, 10p21, 10q11.1, 10q22 (KCNMA1), 11q13,
11q23 (GRIK4), 12q12, 12q13-q15, 12q21-q21.33,
17p11.2-p12, 17q21 (NGFR), 18q22, and 19p13.1
(NFAT).  Of these amplified sites, 6p11.2-p21, 8q12.1,
8q24.13, 12q12, 12q13-q15, 12q21-q21.33, 16p13 and
17p11.2-p12 were frequent.
Gain of clones from 6p12-p21 regions was noted in 33/48
(~65%) cases analyzed. High-level amplification of the
clones from same region was noted in 25% of the cases by
array CGH. We found that most of the cases with amplifi-
cation of 6p12-p21 displayed either increased or slightly
varying degree of copy number increase across the 6p12-
p21 region. The combined log ratios from all the cases
defined the boundaries of amplification between RP3-
329A5 and RP11-79F13. The amplicon spans approxi-
mately 9.4 Mb with amplification peak for clone RP11-
81F7. Further, we used FISH to validate 6p amplicon on
tumor metaphase and interphase cells from cases 274,
364, 426 and 527. Increased copy numbers for clones
RP11-91E11, AL391415, RP11-81F7, RP11-79I2, RP11-
90H17 and RP11-79F13 were noted in interphase cells
with maximum copy number increase for clone RP11-
81F7 (Figure 4A). This was consistent with amplification
peak for clone RP11-81F7 in the tumors profiled by array
CGH (Figure 2B). In addition, we used 2-sample t-test
with randomized variance model to define significant
clones from 6p12-p21 amplicon. By this method, we
identified RP11-79F13 (p = 0.00000007), RP11-79I2 (p =
0.00000007) and RP11-81F7 (p = 0.00000007) as statis-
tically significant clones.
Most cases with 8q gain, displayed varying degree of copy
number increase predominantly from 8q12.1 (16.9%),
8q21.13 (29%), and 8q24.3 (35%). High-level amplifica-
Table 3: Most frequently gained clones.
Clone Map Position (Mb) Cyto Position Frequency (%) Genes
RP11-81F7 43.8 6p21.1 45 HGNC, MRLP14
RP1-163G9 2.6 1p36.32 43 PRDM16
RP11-79F13 44.6 6p21.1 37.5 CDC5L, HSPCB, NFKBIE
RP11-90H17 46.5 6p12.3 37.5 UCP4
RP11-64L12 0.68 16p13.3 37.5 MSLN, SOX8
RP11-637F16 144.61 8q24.3 35.4
RP3-447E21 46 6p21.1 35.4 CLIC5
RP11-79I2 43.4 6p21.1 31.2 EGFL
RP11-80F24 78.3 8q21.13 29
RP4-753D5 50.9 6p12.3 29 TFAP2B
AC005263 0.95 19p13.3 29 AMH, GNRPX, DIT1L
RP11-189D22 19.56 17p11.2 29 TPP3A, SMCR5, DRG2, FLI
RP11-89P19 119.5 8q23.3 27
RP11-89H1 77.4 8q21.13 25
RP11-88N2 43.7 21q22.3 25 SNF1LK
RP1-283E3 1.5 1p36.33 25 CDC2L2, GNB1
RP11-89P9 125.4 8q24.13 22.9 MTSS1
AL391415 43.06 6p21.2 22.9 GLO1, DNAH8
RP11-492I23 3.64 4p16.2 22.9
RP1-163M9 16.2 1p36.13 22.9
RP11-383B15 2.89 19p13.3 22.9
RP11-89K6 13.1 17p12 22.9
RP11-89K10 127.3 8q24.13 20.8 NSE2
RP11-90D11 98.8 8q22.1 20.8
RP11-91E11 37.4 6p21.2 20.8 PIM1
RP3-417I1 63.04 6p11.2 20.8 BAG2, RAB23
RP11-79O4 19.9 17p11.2 20.8 ULK2, AKAP10
RP11-46C24 101.27 16q24.3 20.8
RP11-91K23 67 12q14.3 20.8BMC Cancer 2004, 4:45 http://www.biomedcentral.com/1471-2407/4/45
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tions were also noted from 8q12.1 (RP11-550I15 – 6.3%;
Figure 2C), 8q21.13 (RP11-89H1 – 6.3%), 8q24.3 (RP11-
89K10 – 6.3%) and RP11-637F16 (12.5%). FISH using
clone RP11-89K10 (p = 0.00049) on interphase cells from
case 527 confirmed the amplification (10–12 copies)
(Figure 4B).
Amplification of 12q was noted in 14/51 (~27%) tumors
analyzed by array CGH. Three distinct amplicons – AMP1
(12q12), AMP2 (12q14.1) and AMP3 (12q21.33) were
noted across the entire long arm of chromosome 12 (Fig-
ure 2D). Of these 14 cases, four of them (80, 123, 248,
341) displayed all three amplicons. The AMP1 was noted
in 10 cases covering 1.8 Mb region between RP11-91K15
and RP11-90I21 with peak amplification for clone RP11-
A representative chromosome profiles showing homozygous deletions (A, E) and high-level amplifications (B- E) Figure 2
A representative chromosome profiles showing homozygous deletions (A, E) and high-level amplifications (B- E). The clones 
showing homozygous deletions from 3p14.1 (RP11-89A12) and 17q12 (RP11-79O9) in tumor 06 (A, E) and high-level amplifi-
cations from 6p12-p21 in tumor 248(B), 8q12 in tumors 06 and 341 and 8q23-q24 in tumor 06, (C), 12q13-q15 in tumor 48, 
(D) and 17p11.2 in tumor 06(E), are shown as log ratios (Y-axis). The clones on each chromosome are arranged (pter to qter) 
on the basis of UCSC mapping positions.BMC Cancer 2004, 4:45 http://www.biomedcentral.com/1471-2407/4/45
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91K15 (p = 0.00000004). Another amplicon (AMP2) was
noted 24.48 Mb distal to AMP1 between RP11-91K23 and
RP11-89P15. The AMP3, which was 23.3 Mb distal to
AMP2 containing RP11-89F6.
Amplification of 17p11.2 was noted in 27% of the cases
analyzed by array CGH. The amplicon was composed of
three clones RP11-64B12 (p = 0.0000014), RP11-89K6 (p
= 0.00000005) and RP11-189D22 (p = 0.0000001) and
covering 3.7 Mb region on the short arm of chromosome
17 (Figure 2E). We used these three clones as FISH probes
to validate 17p amplicon in tumors 274, 364, 425 and
628 on interphase/ metaphase cells. The distribution of
copy number for this amplicon in all the cases ranged
from 4–14 copies with peak amplification for clone RP11-
189D22 (10–14 copies), followed by and RP11-89K6 (8–
10 copies) RP11-64B12 (6–8 copies) (Figure 4C).
Discussion
This study represents the first application of genome-wide
copy number changes by array CGH in osteosarcoma.
Recent studies in breast, renal and bladder cancer showed
the potential assessment of this technology in detecting
high-resolution copy number changes [9,11,14]. This
approach will augment the identification of cancer caus-
ing genes by relating the clone information directly with
sequence information from human genome database. In
this study, we used array CGH to screen for high-resolu-
tion DNA copy number changes and precise identification
of amplifications in a panel of 48 osteosarcomas.
Gene amplification is an important genetic mechanism in
human cancers, as it clearly associated with tumor pro-
gression and has a prognostic significance and has even
provided a target for therapeutics [17,18]. These amplifi-
Ideogram showing recurrent homozygous deletions (left) and high-level amplifications (right) identified by array CGH in 48  cases Figure 3
Ideogram showing recurrent homozygous deletions (left) and high-level amplifications (right) identified by array CGH in 48 
cases. The gene(s) contained within the BAC clone are shown in parentheses of the respective clones. Gene(s) present in the 
BAC clones were identified using UCSC browser http://genome.ucsc.edu/cgi-bin/hgGateway?org=human by downloading gene 
table (refFlat) from human gene assembly, July 2003. The ideograms for chromosomes 6, 8, 12 and 17 are shown separately.BMC Cancer 2004, 4:45 http://www.biomedcentral.com/1471-2407/4/45
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cations are often seen at the cytogenetic level as
homozygously staining regions (hsrs) or double minute
chromosomes (dms). However, cytogenetic recognition
of amplifications doesn't contribute to the mapping and
identification of amplified DNA sequences. The advent of
CGH points an ever-increasing number of chromosomal
amplifications in various tumors. These amplifications
contribute to the genomic instability in tumors. We have
recently shown that the mutation of p53 significantly cor-
relates with genome-wide DNA instability and seems to
represent a major genetic factor contributing to the
extremely high levels of genomic instability found in
high-grade osteosarcomas [19].
Our analysis have identified frequently amplified clones
from 6p11.2-p21, 8q12.1, 8q24.13, 12q12, 12q13-q15,
12q21-q21.33, 16p13 and 17p11.2-p12. Amplification of
clones from 6p12-p21 region was noted in 25% of the
cases analyzed. This was consistent with the previously
published results by CGH. By array CGH, we refined the
6p amplicon to 9.4 Mb with amplification peak for clone
RP11-81F7. We recently demonstrated the origin of 6p
amplicon as consequence of tandem duplication of clones
RP11-81F7 and RP11-79F13 [7]. Based on combined
array CGH and FISH analysis suggest CDC5L, HSPCB, and
NFKBIE, and HGNC  and MRPL14  are the target genes
from 6p12-p21 amplicon. Of these genes, CDC5L may be
an important gene in cancer because of its role as a posi-
tive cell cycle regulator for G2/M transition[20].
Consistent with our analysis, overexpression of HSPCB
was shown recently by cDNA microarray studies on oste-
osarcoma [21]. This protein was shown to play an impor-
tant role in assemble/disassembly of tubulin by inhibiting
tubulin polymerization.
High-level amplifications were also noted from 8q12.1
(RP11-550I15 – 6.3%), 8q21.13 (RP11-89H1 – 6.3%),
8q24.3 (RP11-89K10 – 6.3%) and RP11-637F16 (12.5%).
There were no candidate genes present in clones RP11-
550I15, RP11-89H1 and RP11-637F16, but clone RP11-
89K10 contained NSE2 (breast cancer membrane protein
101 kDa) gene.
High-level amplification of clones on 12q revealed three
distinct sites of amplifications – AMP1 (12q12), AMP2
(12q14.1) and AMP3 (12q21.33). Pervious studies have
shown the amplification GLI, CHOP, SAS, HMGI-C,
CDK4,  HDM2,  and  PRIM1  from 12q13-q15 region in
osteosarcoma [22,23]. The present array CGH analysis
identified a possible target gene IFNG from AMP2 (RP11-
298M11; p = 0.0000001), which is physically mapped
close to the HDM2 oncogene locus[24]. Previous studies
demonstrated that T-cell production of IFNG  strongly
suppresses osteoclastogenesis by interfering with the
RANKL-RANK signaling pathway. IFNG  induces rapid
degradation of the RANK adaptor protein, TRAF6, result-
FISH validation of some of the high-level amplifications (6p12.1, 8q24.3 and 17p11.2) identified by array CGH Figure 4
FISH validation of some of the high-level amplifications (6p12.1, 8q24.3 and 17p11.2) identified by array CGH. Interphase cells 
hybridized with centromere 6 (red)/RP11-81F7 (green) in case 274 (A), RP11-89K10 (red) in case 527 (B) and RP11-189D22 
(red) in case 364 (C). The ploidy of these cases was determined based on the modal chromosome number of the respective 
cases, e.g. diploid (case 426) triploid (cases 274 and 364), and tetraploid (case 527).BMC Cancer 2004, 4:45 http://www.biomedcentral.com/1471-2407/4/45
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ing in strong inhibition of the RANKL-induced activation
of the transcription factor NFKB and JNK [25]. The AMP3,
which was 23.3 Mb distal to AMP2 containing RP11-
89F6. Our analysis from AMP3 revealed two interesting
candidate genes: transcription factor ELK3 and PCTAIRE
protein kinase 2 (PCTK2). ELK3 is a member of the ETS-
domain transcription factor family and the protein is acti-
vated by signal-induced phosphorylation [26]. The pro-
tein encoded by PCTK2  belongs to the cdc2/cdkx
subfamily of the ser/thr family of protein kinases and play
an important role in the regulation of the mammalian cell
cycle [27]. High-level amplification of three clones from
12p13 was noted in case 27 and the amplicon span 4.6
Mb with peak amplification for clone RP11-89D16. No
candidate genes contained with in this BAC. Amplifica-
tion 12p has been reported previously in 9/19 high-grade
osteosarcomas by CGH. Recent FISH analysis has identi-
fied the amplification of CCND2, ETV6, and KRAS2 from
12p region [28].
Amplification of 17p11.2 was noted in 27% of the cases
analyzed by array CGH. Our array CGH analysis has iden-
tified three clones with high-level amplifications that
spans ~3.7 Mb region on 17p11.2. Several candidate
genes were identified within these clones (TPP3A,
SMCR5, DRG2, FL11,  MYCD, SOX 17, ELAC2, and
PMP22). Recent studies have shown the amplification of
some of the genes identified in the present study (PMP22,
and TOP3A) from 17p11.2-p12 in high-grade OS by semi-
quantitative PCR and cDNA microarrays [29,30].
The present array CGH analysis has identified seven recur-
rent clones exhibiting homozygous deletions from
1q25.1, 3p14.1, 13q12.2, 4p15.1, 6q12, 6q12 and
6q16.3. These chromosomal regions were consistent with
previously reported studies by loss of heterozygosity
(LOH) and CGH [3-7,31]. The clone, RP11-90M15
(13q12.2) contain possible candidate gene MTMR6, a
protein-tyrosine phosphatase gene and shown to be
present within a cloned region that encompasses a trans-
location breakpoint t(8;13) in an atypical myoprolifera-
tive disorder [32]. Homozygous deletions of two clones
spanning approximately 2.6 Mb of 6q12 region contain-
ing candidate genes – nuclear fragile X mental retardation
protein interacting protein 1 pseudogene (NUFIP1P) and
BAI3  gene (brain-specific angiogenesis inhibitor gene),
which is to homologous to BAI1 and shown to suppress
glioblastoma [33].
Conclusions
In summary, high resolution array-based CGH revealed
large number of chromosomal aberrations previously
identified in osteosarcoma by chromosomal CGH and
conventional cytogenetic methods. The present study
allowed precise identification of smaller DNA copy
number alterations, which suggest the presence of specific
target genes in osteosarcoma. Although this study sug-
gested several possible target genes from amplified
regions from 6p, 8q, 12q and 17p, but these genes should
be validated by other molecular and immunohistochemi-
cal approaches on well-defined large patient samples. Fur-
ther, interaction or association studies between small
genomic losses and gains will facilitate the identification
of new genetic pathways in the pathogenesis of
osteosarcoma.
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